Introduction
C-src is the prototype of a closely related family of nine genes encoding non-receptor membrane-associated protein tyrosine kinases (PTK). In a variety of cell types, Src family members participate in regulation of diverse functions, including proliferation, cell cycle, migration, adhesion, and differentiation (reviewed by Thomas and Brugge, 1997) . In the life cycle of normal colonic epithelial cells and in progressive stages of colon cancer development and progression, specific alterations of Src activity have been observed (reviewed by Jessup and Gallick, 1992) . In the intestinal mucosa, proliferative cells in the base of crypts express Src of high specific activity; in contrast, differentiated cells at the tips of intestinal villi are decreased in Src activity (Cartwright et al., 1993) . In tissue culture systems, differentiation of colon tumor cells is accompanied by similar decreases in Src activity (Foss et al., 1989) . Thus, regulation of Src activity appears critical to proliferation and differentiation of colonic epithelial cells.
In the normal colon, enterocytes at the villous tips of crypts undergo rapid apoptosis accompanied by shedding into the lumen (Gavrieli et al., 1992; Hall et al., 1994; Strater et al., 1995) . In human intestinal epithelial cells, anoikis (detachment-induced apoptosis) occurs within 3 h, mediated by initiator caspases 2 and 9 (Grossmann et al., 2001) . Resistance to anoikis is a common property of many tumors of epithelial cells, and can occur through a variety of mechanisms. Activated oncogenes such as Src and Ras (Frisch and Francis, 1994) ; overexpression of FAK (Frisch et al., 1996) , and activation of growth factor receptors (Jost et al., 2001; Rosen et al., 2001) all have been implicated in anoikis resistance. As many of these alterations occur during colon tumor progression, an understanding of which are critical to anoikis will lead to better insights into the mechanisms of tumor progression. While the role for activated c-Src in these specific events has yet to be established, recent work has demonstrated that Src may be involved in the regulation of multiple survival pathways in epithelial cells (reviewed by Schlessinger, 2000) . In rat intestinal epithelial cells, v-Src expression is sufficient to induce anoikis resistance, in part by increasing Bcl-x L expression (Coll et al., 2002) . Transforming growth factor alpha inhibits anoikis in intestinal epithelial cells, in part through a Src-mediated pathway (Rosen et al., 2001) . In contrast, Src overexpression, which occurs in many tumors (reviewed by Irby and Yeatman, 2000) may sensitize cells to a variety of apoptotic stimuli (Zhong et al., 2002) . Thus, the role of Src in survival pathways is likely to depend upon both the cell type and the activation status of Src.
Increased specific activity of Src is observed in 480% of colon adenocarcinomas relative to normal colonic mucosa (Bolen et al., 1987; Cartwright et al., 1989; Talamonti et al., 1993) . Further increases in Src are seen in metastases relative to primary tumors Termuhlen et al., 1993) . Thus, in the majority of colon tumor cells, Src is constitutively active. Recently, a subset of human colon tumors has been found to contain an activating mutation in the Src gene (Irby et al., 1999) , although such mutations were not observed in other patient populations (Daigo et al., 1999; Wang et al., 2000) . Regardless of the mechanism of activation, our laboratory and others demonstrated that Src activation contributes to increased tumorigenicity of human colon cancer cell lines (Staley et al., 1996; Irby et al., 1997) , partially through the promotion of a signaling pathway deregulating the expression of vascular endothelial growth factor (VEGF) (Ellis et al., 1998) . This study demonstrates that, in colon tumor cell lines, Src activity is one of the factors contributing to resistance to anoikis, and that its contribution to anoikis resistance is independent of the presence or absence of an activated Ras gene.
Results

Src expression and anoikis in human colon cancer cell lines
To determine if Src expression and activity were related to the susceptibility of colon tumor cell lines to undergo anoikis, a panel of five cell lines was analysed. These lines were chosen not only for their varying Src expression and activity, but for differences in FAK expression, as shown in Figure 1 . Further, as summarized in Table 1 , the cell lines consisted of representative colon tumor cell lines with and without K-Ras activation, and differed in differentiation status.
In attached cells, a small population of sub G0/G1 cells was observed in all cultures, ranging from 1.4% in RKO cells to 7.9% in Caco-2 cells. For estimation of anoikis, single cell suspensions from cultures in log phase were maintained for 48 h, after which the per cent of sub G0/G1 (apoptotic) cells was determined, as described in Materials and methods. The per cent of apoptotic cells from the five cell lines maintained under these conditions is shown in Table 1 . HT29 cells, with high Src expression and activity (see Figure 1) were very resistant to anoikis with only 9.7% of sub G0/G1 cells after 48 h suspension. In contrast, SW480 cells with the lowest Src expression were the most sensitive to anoikis, with 70.4% apoptotic cells (see Figure 2 , left panel). SW620 cells (derived from a nodal metastasis from the same patient from which SW480 cells were established) were increased in Src expression and proportionally more resistant to anoikis than SW480 cells. Caco-2 cells, with relatively high Src activity, were also resistant to anoikis (13.7% sub G0/ G1 cells after 48 h detachment), and RKO cells with lower Src activity were more sensitive (58.6% sub G0/ G1 cells after 48 h detachment). Thus, in several colon tumor cell lines, Src expression and activity corresponds with their resistance to anoikis. Figure 1 Expression and activity of c-Src in selected colon tumor cell lines. Each cell line was grown to 70% confluency, and cell lysates were prepared as described in Materials and methods. Activity of Src was determined in the immune complex kinase assay and both autophosphorylation (a) and phosphorylation of the exogenous substrate enolase (b) were determined as described in Materials and methods. Expression of Src (c) was determined by Western blotting. For comparison, expression of FAK is shown (d) with actin expression (e) serving as a loading control 
Effects of increasing and decreasing Src on anoikis
To examine more directly the relationship between Src expression and susceptibility to anoikis, the effects of increasing Src in SW480 cells and decreasing Src in HT29 cells were examined. SW480 cells (with low intrinsic Src expression) were transfected with a csrcY527F expression vector, and stable clones were isolated and expanded, as described in Materials and methods. Expression and activity of Src in SW480 parental, vector-alone transfected cells, and two stable subclones, SW480-2C8 and SW480-3B7, transfected with a Src expression vector are shown in Figure 3 . No increase in Src expression or activity was apparent in vector-transfected cells, whereas SW480-2C8 and SW480-3B7 cells were increased in expression 14-and 18.5-fold, respectively. As shown in Figure 2 and summarized in Table 2 , the intrinsic susceptibility of SW480 cells to anoikis was decreased after expression of c-srcY527F. Further, increased resistance to anoikis corresponded with the amount of Src expressed in the stable transfectants, with 40% SW480-2C8 cells and 24% of SW480-3B7 in the sub G0/G1 fraction following 48 h detachment. In contrast, transfection with the 'empty' vector resulted in no substantial change in the susceptibility of SW480 cells to anoikis with respect to parental cells (not shown).
Next, effects on anoikis of the previously established cell lines HT29-AS15 and HT29-AS33 which were derived by transfection of a c-src antisense expression vector; HT29-S8 derived by transfection of the vector in the 'sense' orientation in to HT29 cells were determined. Expression and activity of Src and Yes in these cells has been reported previously (Staley et al., 1996) . Briefly, HT29-AS15 cells are decreased in Src expression and activity by 4.5-fold and a twofold decrease in expression and activity for HT29-AS33 cells. No differences in expression or activity of c-src were observed in HT29-S8 cells (Staley et al., 1996) . Susceptibility of these cells to anoikis is summarized in Table 2 . Both HT29-AS15 and HT29-AS33 cells are more sensitive to anoikis than parental cells and HT29-S8 cells, with sensitivity proportional to decreased Src expression. These results suggest that in two independent colon adenocarcinoma cell line models, susceptibility to anoikis is proportional to Src expression and activity.
Effect of PD173955 on protein tyrosine kinase activity in vitro
As an independent approach to determining the effect of Src expression and activity on anoikis, the Src family protein tyrosine kinase inhibitor PD173955 (Barvian et al., 1998; Moasser et al., 1999) was used. To determine that this inhibitor selectively affected Src family protein tyrosine kinases from colon tumor cells, the effects of in vitro inhibition of activities in immune complex kinase assays were determined for Src, Yes, and Fak following immunoprecipitation of these kinases from HT29 cells. The results, shown in Figure  4 , demonstrate a dose-dependent inhibition of autophosphorylation of Src and Yes with IC 50 for Src of approximately 300 nM and an IC 50 for Yes of approximately 175 nM. In contrast, no inhibition of Cells were seeded at equal density, grown to subconfluence, trypsinized and placed in single cell suspensions at 378C, as described in Materials and methods. Cells were harvested, fixed, stained with PI, and subjected to FACS analysis as described in Materials and methods. The bar on the graph indicates the sub G0/G1 (apoptotic) cell fraction 
Effects of PD173955 on HT29 cells
The effects of PD173955 were assessed first on HT29 cells, chosen because of their resistance to anoikis (Table 1 ). HT29 cells in culture were incubated in growth media with increasing concentrations of PD173955 for 48 h as described in Materials and methods. Inhibition of cell growth was observed with an IC 50 of 800 nM, however, no morphologic changes were observed by light microscopy (data not shown). High concentrations of PD173955 were shown to arrest the cell cycle at the M phase in a variety of cultured cells (Moasser et al., 1999) . To examine the effects on the cell cycle of HT29 cells subjected to increasing concentrations of PD173955 used in these studies, cell cycle analysis was performed as described in Materials and methods. As shown in Table 3 , with increasing concentrations of PD173955, growth inhibition corresponded with an increased number of cells in the G1 phase of the cell cycle, but no accumulation of cells in G2/M phases. At concentrations of PD173955 greater than 2 mM, an accumulation of cells in M phase was observed (data not shown), consistent with the results of Moasser et al. (1999) . Corresponding with growth inhibition was a dosedependent decrease in both Src and Yes activity, with no effect on expression of these proteins, as shown in Figure 5 . To determine if anoikis was affected by PD173955, HT29 cells were incubated in the presence of the inhibitor, then detached by trypsinization and maintained in suspension, also in the presence of inhibitor as described in Materials and methods. The fraction of sub G0/G1 cells was then estimated by PI staining as described in Materials and methods. As shown in Figure 6a , PD173955 induced no significant change in the number of apoptotic cells in 'attached' cultures, even at the highest concentration of inhibitor tested (1600 nM). However, a dose-dependent increase in apoptosis was observed at 48 h following incubation of HT29 cells in suspension in the presence of PD173955 ( Figure 6a ). The effect of sensitization of HT29 cells to anoikis was further analysed by comparing the rate of anoikis in single-cell suspension, in the presence and absence of PD173955. As shown in Figure 6b , incubation of HT29 cells with 800 nM PD173955 greatly increased the rate of anoikis relative to untreated controls. These results demonstrate that PD173955 sensitizes HT29 cells to detachment-induced apoptosis, with little effect on apoptosis in adherent cells in culture. Sensitivity to anoikis in human colon cancer cell lines incubated with PD173955
The effect of 800 nM PD173955 on anoikis was determined in the panel of cell lines of varying Src expression shown in Figure 1 . The results of treatment with the inhibitor are shown in Table 4 . In detached HT29 and SW620 cells, significantly increased anoikis was observed after 48 h in suspension. In SW480 cells with low Src expression and a high intrinsic susceptibility to anoikis, incubation with PD173955 resulted in no further increases in anoikis. RKO remained resistant to anoikis following incubation with PD173955. RKO cells express the highest levels of FAK of any of the cell lines tested in this study (see Figure 1 ), which may, in part, explain their resistance.
Activation of caspase 3 in detached cells
As an independent confirmation of suspended cells undergoing anoikis, activation of caspase 3 was determined by cleavage of the fluorogenic substrate as described in Materials and methods. Examination of intrinsic differences in abilities of cells to undergo anoikis as measured by caspase 3 yielded results very similar to those obtained by PI staining (data not shown). The effect of PD173955 on induction of caspase 3 was also compared in the cell lines expressing the highest Src, SW480-2C8 and HT29 cells. As demonstrated in Figure 8 , a dose-dependent increase in caspase 3 activation was observed. The dose-dependent increase in anoikis sensitivity in HT29 cells is consistent with the results of PI staining and FACS analysis (Figure 6b ). The results on SW480-2C8 demonstrate that the Src inhibitor can overcome the resistance to anoikis induced by transfection of activated Src, confirming that increased Src activity is responsible for anoikis resistance.
Sensitivity of attached human colon cancer cell lines to staurosporine-induced apoptosis
To determine whether Src activation led to a global increase in apoptosis or a more specific resistance to anoikis, SW480 cells with low Src expression and SW480-2C8 and HT29 cells with high Src expression were subjected to treatment with 100 nM staurosporine for 4 h, and the per cent of cells in the sub G0/G1 population was determined by FACS analysis of propidium iodide stained cells as described in Materials and methods. No significant difference in the sub G0/ G1 cell population was observed among the cells treated with 100 nM staurosporine (Table 5) . Increased apoptosis was observed in a dose-dependent manner, with again no differences observed among these cell lines (data not shown). When 100 nM staurosporine was combined with 1600 nM PD173955 a further approximate twofold increase in the sub G0/G1 population of cells was observed ( Table 5 ), suggesting that PD173955 may confer some sensitivity to staurosporine-induced apoptosis. However, the results demonstrate that increased Src activity alone is not sufficient to confer resistance to apoptosis in adherent colon tumor cells. 
Effect of PD173955 on Akt phosphorylation
Recent experiments in several systems have suggested that Src kinase might be a regulator of Akt-mediated survival pathways. To determine if altered Akt phosphorylation correlated with sensitivity to anoikis, the expression of total Akt, and phospho Akt were compared to that of total and phospho Erk1 and 2 in HT29 cells, SW480 cells and SW480-2C8 cells with and without incubation of PD173955. As shown in Figure  7 , phosphorylation of Akt was increased in SW480-2C8 cells with increased Src expression and activity (see Figure 1 ) relative to parental SW480 cells. Similar results were observed in SW480-3B7 cells with increased Src activity, and with antibodies recognizing Akt phosphorylated at threonine 308 (data not shown).
At increasing concentrations of PD173955, a dosedependent decrease in Akt phosphorylation was observed in each of the cell lines examined. As a positive control, Akt phosphorylation was inhibited by addition of 1 mM wortmannin for 30 min. In contrast, no changes were observed in expression or phosphorylation of Erk1 and 2 in SW480-2C8 cells relative to SW480 cells, and incubation of cells with increased concentrations of PD173955 had no substantial effects on Erk1 and 2 phosphorylation. These results demonstrate that changes in Src activity correspond with changes in Akt phosphorylation.
Effects of the PI3 kinase inhibitor LY294002 on anoikis
The above results suggest that activation of Akt by Src could be a mechanism that contributes to anoikis resistance. To further analyse the potential involvement of Akt, the anoikis-resistant cells HT29 and SW480-2C8 were treated with various concentrations of the relatively selective PI3 kinase inhibitor LY294002 1 h prior to detachment, and apoptosis was determined 48 h later by PI staining followed by FACS analysis or by caspase 3 activation, as described in Materials and methods. As shown in Figure 8 , concentrations of 20 mM LY294002 (which inhibited Akt phosphorylation, data not shown) had similar induction of caspase 3 as that induced by 1600 nM PD173955. Analogous results were observed by PI staining (data not shown). Interestingly, the SW480-2C8 cells were somewhat more resistant to both PD173955 and LY294002-induced anoikis than HT29 cells, correlating with increased Akt phosphorylation in the former cells. Thus, the ability of Src to induce Akt phosphorylation correlates with susceptibility to anoikis.
Effects of PD173955 on Bcl-X L expression
Finally, as the recent data has demonstrated that the ability of V-Src to increase resistance to anoikis in intestinal epithelial cells correlates with increased Bcl-X L expression (Coll et al., 2002) we examined the effects of the Src inhibitor, PD173955 on Bcl-X L in Figure 7 Effect of PD173955 on phosphorylation of Akt and Erk 1 and 2. Cells were grown and incubated in the absence or presence of indicated concentrations of PD173955 as described in Figure 5 , or in the presence of 1 mM wortmannin (last lane).
Western blotting for phospho Akt, total Akt, phospho Erk 1 and 2, and total Erk 1 and 2 was performed as described in Materials and methods. attached and detached HT29 cells. As shown in Figure  9 , no change in Bcl-X L expression was observed upon addition of 800 and 1600 nM PD173955 48 h prior to cellular detachment or when detached cells were maintained in the same inhibitor concentration after detachment. These results suggest that, at least in some colon tumor cell lines, expression of Bcl-X L does not contribute to anoikis resistance mediated by Src.
Discussion
Increased specific activity of Src, whether due to infrequent mutation (Irby et al., 1999) or other mechanisms such as altered protein/protein association, is a hallmark of most colon tumors (Bolen et al., 1987; Cartwright et al., 1989; Talamonti et al., 1993) . Furthermore, Src activity increases at progressive stages of the disease Termuhlen et al., 1993) and is predictive of poor clinical prognosis (Allgayer et al., 2002) suggesting that Src activation confers growth and/or survival advantages to metastatic colon tumor cells. To understand possible roles for Src in promotion of colon tumor metastasis, we have examined the role of Src in regulating biologic processes required for the development of metastasis. Previously, we have demonstrated that increased Src activity leads to constitutive expression of VEGF in HT29 cells, as well as the ability of hypoxia (Ellis et al., 1998) and cell density (Fleming et al., 1997) to upregulate this critical angiogenic molecule. The current study examines another crucial aspect of cells that develop metastases, the ability to survive after detachment at their primary site of growth. The critical role of extracellular matrix in survival of colonic epithelial cells is demonstrated by the very rapid apoptotic death (within 3 h) that follows detachment (Grossmann et al., 2001 ). This result is not surprising, given the rapid proliferation of colonic epithelial cells in the base of crypts and the short normal lifespan of differentiated colonocytes. Resistance to detachmentinduced apoptosis, or anoikis, is a common property of tumor cells considered to be crucial to the development of metastases. As demonstrated in this study, anoikisresistant colon tumor cells can survive more than 48 h in suspension with little loss of viability. While several molecular alterations in colon tumor cells are likely to contribute to anoikis-resistance, our work and that of others suggest that Src activation is one of the key mediators of this phenotype. Recent studies have demonstrated that v-Src induces resistance to anoikis in intestinal epithelial cells (Coll et al., 2002) ; and in rat intestinal epithelial cell lines, Src activity contributes to resistance to anoikis conferred by TGFa (Rosen et al., 2001) . While these studies have focused on the role of Src in normal intestinal cells, the current work focuses on colon tumor cell lines, which have undergone a number of genetic alterations including frequent Src activation (Bolen et al., 1987; Cartwright et al., 1989; Talamonti et al., 1993; Termuhlen et al., 1993) . Cells with low Src activity such as SW480 cells were much more sensitive to anoikis than cells with intrinsically high Src activity, or SW480 cells transfected with activated Src. Interestingly, SW480 cells harbor an activated K-Ras, suggesting that Ras activation is not the most critical regulator of anoikis-resistance over 48 h. However, activated Ras has been demonstrated to contribute to anoikis resistance in a variety of cells, including colonic intestinal cells (Rosen et al., 1998 (Rosen et al., , 2000 . Our studies do not rule out a contribution of activated Ras in anoikis resistance, as SW480 cells, for example, undergo no measurable anoikis after 3 h (data not shown) in marked contrast to normal intestinal epithelial cells (Grossmann et al., 2001) . Our results do suggest that Src activation is more critical to longer-term survival, an important property of cells that must survive in circulation prior to growth at a distant (metastatic) site.
A variety of mechanisms have been demonstrated to contribute to anoikis (reviewed by Frisch and Screaton, 2001) . Several of these, including integrin-mediated signaling and signaling through growth factor receptors, involve activation of the PI3 kinase/Akt pathway. Roles of integrin-mediated survival occur, in part, by activating Focal Adhesion Kinase (FAK) (Burridge et al., 1992; Guan et al., 1991; Huang et al., 1993; Kornberg et al., 1992; Lipfert et al., 1992) . Detachment of epithelial cells from the extracellular matrix leads to rapid caspase 3-mediated degradation of FAK (Gervais et al., 1998) , cessation of the PI3 kinase-mediated survival signal, and anoikis (Frisch et al., 1996) . Interestingly, FAK is overexpressed in most human colon tumors, with additional increases in expression correlating with tumor progression (Weiner et al., 1993) .
FAK phosphorylation also leads to FAK association with Src (Schaller et al., 1994) , resulting in increased PTK activity of Src. Protein complexes containing FAK, Src and other signaling and structural proteins mediate several cellular processes, including cytoskeletal organization, migration and in addition promote cellular survival pathways through activation of PI3 Figure 9 Effect of PD173955 on expression of Bcl-X L in HT29 cells. Subconfluent HT29 cells were incubated with the indicated amount of PD173955 for 48 h, then either harvested (attached) or detached and maintained in media with indicated concentrations of PD173955 as described in Materials and methods. Bcl-X L expression was determined by immunoblotting, with actin as a loading control kinase (reviewed by Howe et al., 1998) . Association of FAK with Src persists as long as cells, are in contact with the extracellular matrix (Defilippi et al., 1994) . Detachment of normal epithelial cells from the extracellular matrix leads to dephosphorylation of FAK and dissociation of FAK/Src complexes, followed by apoptosis, termed anoikis (Frisch and Francis, 1994; Khwaja et al., 1997) . Due to loss of integrins, normal regulatory pathways mediated by the extracellular matrix are disrupted in colon tumor cells. Thus, enforced expression of the a5b1 fibronectin receptor in HT29 colon adenocarcinoma cells leads to decreased Src activity, and increased responsiveness to extracellular matrix components (Schmidt et al., 1998) .
Whether Src is required for FAK-mediated anoikis is uncertain. Src itself plays important roles in integrin-mediated signaling events. V-src transformed cells possess FAK/Src complexes resistant to dissolution upon cellular detachment, decreased degradation of FAK and resistance to anoikis (Frisch et al., 1996) . Src7/7 fibroblasts are deficient in migration, another important integrin-mediated signaling event (Klinghoffer et al., 1999) . Thus, increases in Src activity through FAK association may contribute to anoikis resistance. However, our data suggest that Src kinase activity, not scaffolding function, is important to Srcmediated anoikis resistance. PD173955, which sensitizes resistant colon tumor cells to anoikis is a competitive inhibitor for the ATP binding site (Barvian et al., 1998) and would not be expected to affect Src interactions. To confirm the role of kinase activity in anoikis resistance we used a dominant negative Src deficient in kinase activity (Mukhopadhyay et al., 1995) , which also increased sensitivity of colon tumor cells to anoikis (although expression of this construct sensitized cells more globally to apoptosis -data not shown)
Thus, Src and FAK may contribute independently to anoikis resistance. Such a possibility is supported by results of Fincham et al. (2000) demonstrating that vSrc does not require FAK for its association with focal adhesions. Rather, focal adhesion targeting correlates with the ability of v-Src to associate with the p85 subunit of PI3 kinase. This association is also sufficient for activation of Akt (Fincham et al., 2000) . Our studies strongly suggest that a critical role of Src activation in promoting resistance to anoikis is the ability of Src activation to induce Akt phosphorylation. In SW480 2C8 cells transfected with activated Src, increased anoikis resistance correlated with increased Akt phosphorylation. Conversely in anoikis-resistant HT29 cells, the ability of the Src inhibitor PD173955 to sensitize cells to anoikis correlated with decreased Akt phosphorylation. The inhibitor of PI3 kinase, LY294002 was itself sufficient to sensitize colon tumor cells to anoikis. Thus, Src-induced Akt phosphorylation appears critical to anoikis resistance in colon tumor cells. While Src may associate directly with PI3 kinase leading to its activations, recently, v-Src was demonstrated to phosphorylate Akt directly on tyrosines 315 and 326, a process thought to be important to activation of some Akt survival functions, such as increased FKHR transcription . Thus, Src may contribute directly to Aktmediated survival. Src family members are also required in vivo for promotion of Akt-mediated survival pathways downstream from TNF receptor, and may also affect apoptosis in large-intestinal epithelial cells (Xiang et al., 2001) . The role of death receptors in anoikis, however, remains controversial (reviewed by Frisch and Screaton, 2001 ).
Other pathways have been linked to Src-mediated resistance to anoikis. Transformation by viral Src results in upregulation of the anti-apoptotic protein Bcl-X L (Karni et al., 1999) . In intestinal epithelial cells, v-Src-induced expression of Bcl-X L mediates, in part, resistance to anoikis. Resistance to anoikis in these vSrc expressing cells appears to result from activation of Erk1/2 (Coll et al., 2002) . In contrast, we demonstrate no alteration of Erk activity in response to increased or decreased Src activity in colon tumor cells (Figure 7) . Further, we observed no decrease in Bcl-X L expression upon sensitization of colon tumor cells to anoikis with the Src inhibitor, PD173955 (Figure 9 ). These results suggest that v-Src may be inducing additional pathways to those induced by the wild type (but high specific activity) Src in colon tumor cells, as well as Src Y527F, a less potent transforming protein than v-Src (Kmiecik and Shalloway, 1987) . Alternatively, the additional genetic alterations of colon tumor cells may lead to changes in Erk regulation. In support of this latter possibility, Weng et al. (2002) demonstrated recently that activation of b-catenin confers resistance to anoikis. Thus, some of the increased resistance to anoikis of colon tumor cells such as SW480 with low Src activity is likely due to activation of survival pathways such as those mediated by b-catenin and Kras, and additional resistance is conferred upon the cells by Src activation. This possibility is consistent with Src activation in human colon tumors leading to poor clinical survival (Allgayer et al., 2002) .
The results of this study add to a growing list of Srcmediated functions associated with cellular survival, suggesting that selection of cells with Src activation results in distinct advantages to tumor cells. Growth of the primary tumor requires neovascularization, and not only does Src activation contribute to the expression and induction of VEGF (Ellis et al., 1998; Garcia et al., 1991) , Src may be required as well for response of endothelial cells to this angiogenic molecule (Eliceiri et al., 1999) . Src appears to regulate VEGF-mediated vascular permeability in the brain following stroke and suppression of Src activity decreases this permeability, thus lessening brain injury (Paul et al., 2001) . Aside from a role in anoikis, Src may couple lymphokine receptor activation with the inhibition of apoptosis (Wong et al., 1999) . Thus, Src activation in tumor cells may lead to coordinate derepression of multiple survival pathways critical to tumor cell progression. Therefore, selective Src inhibitors, such as PD173955 may have therapeutic benefit in inhibiting progression of tumors with Src activation.
Materials and methods
Cell culture
HT29, SW480 and SW620 cells were maintained in DMEM/ F12 (Life Technologies, Inc., Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT, USA). Stable HT29 subclones decreased in Src expression following transfection with Src antisense expression vectors have been described previously (Staley et al., 1996) . These cells, and stable SW480 subclones (SW480-2C8 and SW480-3B7) expressing c-srcY527F expression vector constructs were maintained under the abovedescribed conditions, except for the addition of 300 mg/ml G418 to the culture medium. RKO cells were maintained in McCoy's 5A medium; Caco-2 cells in Minimal Essential Medium, and Jurkat cells in RPMI, each supplemented with 10% fetal bovine serum.
Cell cycle analyses
Samples containing 1 -2610 6 cells were washed once in phosphate-buffered saline (PBS) then fixed in 70% ethanol and stored at 48C. At the time of analysis, samples were washed once in PBS, then stained with 50 mg/ml propidium iodide (PI) (Calbiochem, La Jolla, CA, USA), 20 mg RNase A (Sigma, St Louis, MO, USA), 0.5% Tween 20 (Sigma) in phosphate buffered saline (PBS) and incubated at 378C for 20 min. Samples were then analysed by fluorescence activated cell sorting (FACS) using a flow cytometer (Coulter Epics XL-MCL, Coulter Corp., Miami, FL, USA).
Anoikis studies
Cells were grown to 80% confluence in 100-mM tissue culture dishes, unless otherwise noted in the text, then trypsinized and resuspended as a single cell suspension in complete media. Suspended cells were continuously rotated at 378C in a standard tissue culture incubator under 5% CO 2 . After varying time intervals, cells were subjected to PI staining and FACS analysis as described above. The values presented represent the average of three independent experiments.
Caspase 3 activation assays
Caspase 3 activation was determined with the use of a fluorigenic substrate. Briefly, 1610 6 cells were lysed in 200 ml of lysis buffer (100 mM HEPES, pH 7.5, 10% sucrose, 0.1% CHAPS, 10 mM DTT, 2 mM PMSF and complete mini inhibitor tablet (Roche)) for 1 h on ice. Clarified lysate was incubated with 2 ml AC-DEVD-AMC (N-acetyl-asp-glu-valasp-(7-amino-4-methylcoumarin)) (Enzyme Systems, Livermore, CA, USA) substrate (stock concentration 25 mM) for 30 min at 378C. As a negative control, 200 ml lysis buffer was incubated with 2 ml of AC-DEVD-AMC substrate under identical conditions. After incubation, lysis buffer was added to a final volume of 2 ml. The released AMC was measured with a spectrofluorometer with an excitation wavelength of 380 nM and an emission wavelength of 460 nM. (Barvian et al., 1998; Moasser et al., 1999) . PD173955 was maintained as a frozen stock at 10 mM concentration in DMSO. For studies with the inhibitor, PD173955 was added 16 h after the cells were seeded. For anoikis studies, suspended cells were maintained in the same PD173955 concentrations used in attached cell cultures. LY 294002 (Sigma, St Louis, MO, USA) and wortmannin (Sigma) were used as selective inhibitors of PI3 kinase. For studies on anoikis, 20 mM LY 294002 was added to the medium 1 h prior to cell detachment, then maintained in medium of cells in suspension. Staurosporine (Sigma) was used to induce apoptosis in attached cells. Staurosporine was added at indicated concentrations to cell cultures for 4 h, after which apoptosis was estimated by PI staining and FACs analysis or by caspase 3 activation.
Transfection
To increase Src expression and specific activity in SW480 cells, the c-srcY527F construct (containing the c-src coding sequence harboring a tyrosine to phenylalanine substitution at codon 527) of Kmiecik et al. (1987) was used, as described previously (Allgayer et al., 1999) . Briefly, the Src sequence was excised and cloned into the HindIII/BamHI cloning site of PCDNAIII (Invitrogen Corp., Carlsbad, CA, USA), thus allowing for selection of G418-resistant clones. This plasmid was transfected into SW480 cells using LipofectAMINE (Life Technologies, Inc., Grand Island, NY, USA), according to manufacturer's instructions, single cells were expanded, and clones were screened for Src expression and activity.
Immunoprecipitation and immune complex kinase assays
Cells were rinsed with ice-cold PBS then detergent lysates were made in a standard radioimmune precipitation assay buffer (Garcia et al., 1991) . Cells were homogenized and clarified by centrifugation at 10 000 g. Cell lysates (250 mg protein) were reacted for 2 h with either monoclonal antibody 327 (Oncogene Research Products, Cambridge, MA, USA) for immunoprecipitation of Src, monoclonal Anti-FAK antibody (clone 2A, Upstate Biotechnology, Inc., Lake Placid, NY, USA), or the mouse monoclonal antibody to Yes, 1B7 (WAKO Biologicals, Richmond, VA, USA). Immune complexes were formed by the addition of 6 mg of rabbit anti-mouse IgG (Organon Teknika, Durham, NC, USA) for 1 h, followed by 50 ml of 10% (v/v) formalin-fixed Pansorbin (Staphylococcus aureus, Cowan strain; Calbiochem, La Jolla, CA, USA) for 30 min. Pellets were then washed three times in a buffer consisting of 0.1% Triton X-100, 150 mM NaCl and 10 mM sodium phosphate. Immune complex kinase assays were performed by standard procedures as described previously (Garcia et al., 1991) . Briefly, reactions were initiated at 228C by the addition to each sample of 10 mCi of [g 32 P]ATP, 10 mM Mg 2+ and 100 mM sodium orthovanadate in 20 mM HEPES buffer. To analyse phosphorylation of an exogenous substrate, 10 mg rabbit muscle enolase (Sigma) was added to the reaction buffer. After 10 min, reactions were terminated by the addition of SDS sample buffer. Proteins were separated by SDS -PAGE on 8% polyacrylamide gels, and radioactive proteins were detected by autoradiography.
Immunoblotting
Clarified cell lysates (50 mg/lane) were separated by SDS -PAGE on 8% gels and electroblotted onto polyvinylidene difluoride membranes (Amersham Corp., Chicago, IL, USA) as described previously (Garcia et al., 1991) . Membranes were blocked with 15% skimmed milk in PBS, then incubated with anti-Src (1 : 1000), anti-Yes (1 : 1000), and anti-FAK (1 : 1000) and a mouse monoclonal antibody to actin (1 : 10 000, Sigma). Total Erk1 and Erk2 levels were analysed with a rabbit polyclonal antibody (Oncogene Research Products) at 1 : 1000 dilution; phosphorylated Erk1 and 2 (thr202 and thr204) proteins also were analysed with a rabbit polyclonal antibody (Cell Signaling Technology, Beverly, MA, USA) at 1 : 1000 dilution. Expression of total Akt, and Akt phosphorylated at ser473, were determined with rabbit polyclonal antibodies (Cell Signaling Technology), each at 1 : 1000 dilution. Expression of Bcl-X L was determined with a mouse monoclonal antibody (1 : 1000 dilution, BD Transduction, Lexington, KY, USA). All mouse monoclonal antibodies were followed by horseradish peroxidase-conjugated rabbit anti-mouse IgG (ICN Biochemicals Inc., Costa Mesa, CA, USA); rabbit polyclonal antibodies were followed with horseradish peroxidase-conjugated goat anti-rabbit IgG. Specific binding of antibody was determined using the NEN detection system (NEN Life Science Products, Inc., Boston, MA, USA).
